Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2011

View Archived Issues

Merck KGaA presents novel PDK1 inhibitors with potential to treat cancer

Innovative oral MS therapy advances to phase IIa

Summit identifies new approach to treat Alzheimer's disease

Clinical studies evaluate lersivirine versus efavirenz in HIV and its effect on methadone PK

New androgen receptor antagonists reported

S*BIO discloses novel mTOR inhibitors

Novel histamine H4 receptor antagonists prepared by Palau Pharma

Pfizer divulges new MPGES-1 inhibitors for pain

Japanese company patents new angiotensin AT receptor antagonists/PPAR-gamma agonists

D-Pharm clear to continue phase III DP-b99 study

Phase II Aimspro trial for bladder dysfunction in MS advances

Aeterna Zentaris reports nonclinical milestone for oral prostate cancer vaccine

Millennium files sNDA to add survival data to Velcade MM label in U.S.

Pfizer's new opioid NOP receptor antagonists show preclinical potential to treat AD

Potent serotonin 5-HT4 receptor agonist described by Suven

NanoCarrier and Orient Europharma commence phase II study of Nanoplatin

Cellceutix cleared to conduct phase I trial of anticancer drug

Regulus Therapeutics and GSK alliance identifies third microRNA target

EMA accepts Santhera Pharmaceuticals' idebenone MAA for review

First-in-human trial assesses effects of GSK-1034702 on cognitive function

Merck & Co. and Simcere sign agreement to establish joint venture in China

FDA issues safety warning regarding use of Multaq in patients with permanent AF

Bristol-Myers Squibb to acquire Amira Pharmaceuticals

Manhattan Pharmaceuticals and FDA reach agreement on SPA for phase III AST-726 trial

Apricus files MAA in Switzerland for Vitaros

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...